Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Aeglea BioTherapeutics Has Agreed To Sell The Global Rights To Pegzilarginase, An Investigational Treatment For The Rare Metabolic Disease Arginase 1 Deficiency To Immedica Pharma For $15M In Upfront Cash And Up To $100M In Contingent Milestone Payments

Author: Benzinga Newsdesk | July 27, 2023 07:18am

The sale of pegzilarginase to Immedica supersedes the previous license agreement between Aeglea and Immedica.

Posted In: AGLE